This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Coupang (CPNG) to Release Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Coupan's (CPNG) fourth-quarter results are expected to reflect strength in its logistics and e-commerce businesses.
MercadoLibre (MELI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
MercadoLibre's (MELI) fourth-quarter results are likely to reflect strength in the commerce and fintech businesses.
Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Booking Holdings (BKNG) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Booking Holdings' (BKNG) fourth-quarter results are likely to reflect gains from strength in the agency, advertisement and merchant businesses.
Block (SQ) to Release Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Block's (SQ) fourth-quarter results are likely to reflect portfolio strength amid the coronavirus pandemic.
What's in the Offing for Alibaba (BABA) in Q3 Earnings?
by Zacks Equity Research
Alibaba's (BABA) third-quarter fiscal 2023 results are expected to reflect gains from its International commerce and Cloud segments.
Axonics (AXNX) Soars 10.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
3 Hot Stocks Going Into the Holiday Weekend
by Derek Lewis
All three of these top-ranked stocks have recently gone on nice runs, giving shareholders some holiday cheer. Can the strength spill over into the new year?
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Axonics (AXNX) This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 27.66% and 12.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Is a Surprise Coming for Axonics (AXNX) This Earnings Season?
by Zacks Equity Research
Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Enovis (ENOV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info System Stocks to Gain on Rising Demand for Digital Health
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
Axonics Inc. (AXNX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Axonics (AXNX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Axonics (AXNX) This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Assertio (ASRT) have performed compared to their sector so far this year.
Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 17.54% and 16.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?